Educational aims This article is mainly intended for trainees and specialists who are interested in the management of severe asthma. It aims to inform readers about the updated ERS/ATS recommendations for management of severe asthma, specifically on the topics of biologics, macrolides and long-acting muscarinic antagonists. It also provides guidance on utilisation of available biomarkers in selecting advanced therapies in severe asthma.
